The Annals Summaries of the Latest Medical Research!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 15 July 2008, www.theannals.com, DOI 10.1345/aph.1L066.
 The Annals of Pharmacotherapy: Vol. 42, No. 9, pp. 1290-1297. DOI 10.1345/aph.1L066
© 2008 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Google Scholar
Right arrow Articles by Stevens, D. L
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stevens, D. L

PSYCHIATRY

Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome

Debra L Stevens, PharmD BCPP

Director of Pharmacy Services, Oklahoma DHS Developmental Disabilities Services Division, 2400 N. Lincoln Blvd., 2nd Floor, Oklahoma City, OK 73125, fax 405/522-3037, Debra.Stevens{at}okdhs.org

Reprints: Dr. Stevens

OBJECTIVE: To review the published reports of neuroleptic malignant syndrome (NMS) associated with the use of selective serotonin-reuptake inhibitors (SSRIs) and second-generation antipsychotics.

DATA SOURCE: Information was selected from a MEDLINE search of English-language literature (1950–May 2008). Manual search of all published cases indexed in MEDLINE (English language only) of NMS associated with second-generation antipsychotics was also performed.

STUDY SELECTION AND DATA EXTRACTION: Pertinent information from all reports obtained was included, with specific emphasis on patient age, sex, second-generation antipsychotic involved, SSRI or other antidepressant involved, time of onset of NMS symptoms in relation to medication changes, treatment administered, and outcome of the reaction.

DATA SYNTHESIS: NMS has been reported with every second-generation antipsychotic agent. It is unclear whether concomitant therapy with other agents may increase the risk of NMS development via pharmacodynamic or pharmacokinetic mechanisms or both. The suggested pharmacodynamic mechanism for increased risk of NMS with concomitant use of SSRIs is the effect of serotonin on dopamine release. Serotonin further inhibits dopamine release and thereby may worsen a hypodopaminergic state induced by antipsychotics. Pharmacokinetic factors may also play a role in some NMS cases involving an SSRI by increasing antipsychotic concentrations. An examination of case reports seems to indicate that at least in some cases, a temporal relationship exists with the addition of an SSRI to existing antipsychotic therapy.

CONCLUSIONS: The use of SSRIs may be associated with an increased risk of NMS development in those receiving second-generation antipsychotics. Clinicians should closely monitor patients for the potential development of NMS.

Key Words: neuroleptic malignant syndrome, second-generation antipsychotics, selective serotonin-reuptake inhibitors

Published Online, July 15, 2008. www.theannals.com, DOI 10.1345/aph.1L066




homecopy help contact us subscription past issues search current issue
Copyright © 2008 by Harvey Whitney Books Company.